Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Breaks Above 200-Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s share price passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $5.96 and traded as high as $7.14. Cumberland Pharmaceuticals shares last traded at $7.03, with a volume of 30,401 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Cumberland Pharmaceuticals has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Up 0.7%

The stock has a market capitalization of $105.31 million, a PE ratio of -9.90 and a beta of 0.06. The stock has a fifty day moving average of $7.43 and a 200-day moving average of $5.96.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.07). The company had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 28.81% and a negative net margin of 34.40%.

Cumberland Pharmaceuticals Dividend Announcement

The business also recently disclosed a dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, July 23rd were given a dividend of $1.50 per share.

Institutional Trading of Cumberland Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Cumberland Pharmaceuticals in the second quarter worth approximately $412,000. Bank of New York Mellon Corp acquired a new position in Cumberland Pharmaceuticals during the 2nd quarter worth approximately $379,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Cumberland Pharmaceuticals in the 1st quarter valued at approximately $66,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Cumberland Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock valued at $898,000 after purchasing an additional 4,081 shares during the last quarter. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company headquartered in Nashville, Tennessee. Founded in 1999, the company develops, acquires, and commercializes branded prescription products, with an emphasis on hospital acute care, gastroenterology, and other specialty areas.

Its portfolio has included Caldolor, an intravenous formulation of ibuprofen used for pain and fever; Vaprisol, an injectable treatment for certain cases of hyponatremia; Kristalose, a prescription form of lactulose used to treat constipation; and Omeclamox-Pak, a therapy for Helicobacter pylori infection and associated ulcer disease.